Cutting Edge: Topical Recombinant Nerve Growth Factor for the Treatment of Neurotrophic Keratopathy-Biologicals as a Novel Therapy for Neurotrophic Keratopathy

Cornea. 2022 Jun 1;41(6):673-679. doi: 10.1097/ICO.0000000000002974. Epub 2022 Feb 2.


Ophthalmologists find management of neurotrophic keratopathy (NK) challenging because conventional therapy lacks efficacy and may result in permanent loss of vision. Recombinant nerve growth factor (cenegermin) targets the underlying pathogenesis of NK by regenerating corneal nerves and healing the corneal epithelium through promotion of proliferation, maturing corneal epithelial cells. It has been approved as Food Drug Association-approved treatment of NK. In this article, the background, clinical trials, and impact of recombinant nerve growth factor as the first neurotrophic factor for the restoration of corneal integrity, homeostasis, and corneal nerve regeneration are discussed.

Trial registration: NCT04909450.

MeSH terms

  • Biological Products* / therapeutic use
  • Cornea / pathology
  • Corneal Diseases* / pathology
  • Corneal Dystrophies, Hereditary* / drug therapy
  • Epithelium, Corneal* / pathology
  • Humans
  • Keratitis* / drug therapy
  • Nerve Growth Factor / therapeutic use
  • Ophthalmic Solutions / therapeutic use
  • Trigeminal Nerve Diseases* / drug therapy
  • Trigeminal Nerve Diseases* / pathology


  • Biological Products
  • Ophthalmic Solutions
  • Nerve Growth Factor

Associated data